Answers are grounded in this paper and cite their sources.
The proposed imaging response evaluation guidelines, along with validated clinical outcome measures, will maximize the ability to identify potentially active agents for patients with NF and benign tumors.
No takes yet. Share an insight, caveat, or question.
Dombi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: